Mediators of Inflammation in Chronic Inflammatory Bowel Disease

References

• Lauritsen K, Laursen L S, Bukhave K, Rask-Madsen J. Inflammatory intermediaries in inflammatory bowel disease. Int J Color Dis 1989; 4: 75–90
   PubMed Web of Science ®Google Scholar
• Targan S R, Shanahan F. Inflammatory bowel disease—from bench to bedside. Williams and Wilkins, Baltimore 1994
   Google Scholar
• Wallace J L. Immunopharmacology of the gastrointestinal system. Academic Press, London 1993
   Google Scholar
• MacDermott R P, Stenson W F. Inflammatory bowel disease. Immunology and immunopathology of the liver and gastrointestinal tract, S Targan, F Shanahan. Igaku-Shoin, New York/Tokyo 1990; 459–86
   Google Scholar
• Rask-Madsen J. Eicosanoids and their role in the pathogenesis of diarrhoeal diseases. Clin Gastroenterol 1986; 15: 545–66
   PubMedGoogle Scholar
• Lauritsen K, Hansen J, Bytzer P, Bukhave J, Rask-Madsen J. Effects of sulphasalazine and disodium azodisalicylate on colonic PGE2 concentrations determined by equilibrium in vivo dialysis of faeces in patients with ulcerative colitis and healthy controls. Gut 1984; 25: 1271–8
   PubMed Web of Science ®Google Scholar
• Lauritsen K, Laursen L S, Bukhave K, Rask-Madsen J. Effects of topical 5-aminosalicylic acid and prednisolone on prostaglandin E2 and leukotriene B4 levels determined by equilibrium in vivo dialysis of rectum in relapsing ulcerative colitis. Gastroenterology 1986; 91: 837–44
   PubMed Web of Science ®Google Scholar
• Lauritsen K, Laursen L S, Bukhave K, Rask-Madsen J. In vivo effects of orally administered prednisolone on prostaglandin and leucotriene production in ulcerative colitis. Gut 1987; 28: 1095–9
   PubMed Web of Science ®Google Scholar
• Rampton D S, Collins C E. Review article: thromboxanes in inflammatory bowel disease—pathogenic and therapeutic implications. Aliment Pharmacol Ther 1993; 7: 357–67
   PubMed Web of Science ®Google Scholar
• Lauritsen K, Laursen L S, Bukhave K, Rask-Madsen J. Mediators of the inflammatory reaction. Inflammatory bowel diseases, G Järnerot, J Lennard-Jones, S Truelove. Malmö, Corona, AB 1992; 149–69
   Google Scholar
• Ahnfelt-Rønne I, Nielsen O H, Christensen A, Langholz E, Binder V, Riis P. Clinical evidence supporting the radical scavenger mechanism of 5-aminosalicylic acid. Gastroenterology 1990; 98: 1162–9
   PubMed Web of Science ®Google Scholar
• Brynskov J, Nielsen O H, Ahnfelt-Rønne I, Bendtzen K. Cytokines (immunoinflammatory hormones) and their natural regulation in inflammatory bowel disease. Dig Dis 1994
   PubMedGoogle Scholar
• Cominelli F, Nast C C, Clark B D, Schindler R, Lierena R, Eysselei V E. Interleukin 1 (IL-1) gene expression, synthesis, and effect of specific IL-1 receptor blockade in rabbit immune complex colitis. J Clin Invest 1990; 86: 972–80
   PubMed Web of Science ®Google Scholar
• Cominelli F, Nast C C, Duchini A, Lee M. Recombinant interleukin-1 receptor antagonist blocks the proinflammatory activity of endogenous interleukin-1 in rabbit immune colitis. Gastroenterology 1992; 103: 65–71
   PubMed Web of Science ®Google Scholar
• Roediger W E, Lawson M J, Raddcliffe B C. Nitrite from inflammatory cells: a cancer risk factor in ulcerative colitis. Dis Colon Rectum 1990; 33: 1034–6
   PubMedGoogle Scholar
• Bukhave K, Rask-Madsen J. Prostaglandin E2 in jejunal fluids and its potential diagnostic value for selecting patients with indomethacin-sensitive diarrhoea. Eur J Clin Invest 1981; 11: 191–7
   PubMed Web of Science ®Google Scholar
• Bukhave K, Green K, Rask-Madsen J. Comparison of radioimmunological determinations with gas chromatography mass spectrometry dosage. A study of PGE2 and PGF2α in gastrointestinal fluids. Biomed Mass Spectrom 1983; 10: 265–8
   PubMedGoogle Scholar
• Lauritsen K, Laursen L S, Bukhave K, Rask-Madsen J. In vivo profiles of eicosanoids in ulcerative colitis, Crohn's colitis, andClostridium difficile colitis. Gastroenterology 1988; 95: 11–7
   PubMed Web of Science ®Google Scholar
• Laursen L S, Næsdal J, Bukhave K, Lauritsen K, Rask-Madsen J. Selective 5-lipoxygenase inhibition in ulcerative colitis. Lancet 1990; 335: 683–5
   PubMed Web of Science ®Google Scholar
• Hillingsø J, Kjeldsen J, Laursen L S, Lauritsen K, von Sprechelsen S, Depré M, et al. Blockade of leukotriene production by a single oral dose of MK-0591 in active ulcerative colitis. Clin Pharmacol Ther 1995; 57: 335–41
   PubMed Web of Science ®Google Scholar
• Laursen L S, Lauritsen K, Bukhave K, Rask-Madsen J, Jacobsen O, Næsdal J, et al. Selective 5-lipoxygenase inhibition by zileuton in the treatment of relapsing ulcerative colitis: a randomized double-blind placebo-controlled multicentre trial. Eur J Gastroenterol Hepatol 1994; 209–15
   Google Scholar
• Davidsen B D. Concanavalin A induced suppressor activity exerted by peripheral blood mononuclear cells—with special reference to chronic inflammatory bowel disease. Dan Med Bull 1988; 35: 201–22
   PubMedGoogle Scholar
• Elmgreen J. Complement and function of neutrophils in chronic inflammatory bowel disease. Dan Med Bull 1986; 33: 222–8
   PubMed Web of Science ®Google Scholar
• Wandall J H. Neutrophilic granulocyte function: quantitative leukocyte mobilization and function of circulating and exudative neutrophils. Dan Med Bull 1988; 35: 237–52
   PubMedGoogle Scholar
• Nielsen O H. In vitro studies on the significance of arachidonate metabolism and other oxidative processes in the inflammatory response of human neutrophils and macrophages with special reference to chronic inflammatory bowel disease. Scand J Gastroenterol 1988; 23(Suppl 150)1–21
   PubMedGoogle Scholar
• Ahnfelt-Rønne I, Nielsen O H. The antiinflammatory moiety of sulfasalazine, 5-aminosalicylic acid, is a radical scavenger. Agents Actions 1987; 21: 191–4
   PubMedGoogle Scholar
• Nielsen O H, Bukhave K, Ahnfelt-Rønne I, Elmgreen J. Arachidonic acid metabolism in human neutrophils: lack of effect of cyclosporine A. Int J Immunopharmacol 1986; 8: 419–26
   PubMed Web of Science ®Google Scholar
• Brynskov J. Cyclosporin in Crohn's disease: therapeutic and pathogenetic implications. Dan Med Bull 1994; 41: 332–44
   PubMedGoogle Scholar
• Brynskov J, Bagge-Hansen M, Reimert C, Bendtzen K. Inhibitor of interleukin lα and interleukin-1β induced T-cell activation in serum of patients with active Crohn's disease. Dig Dis Sci 1991; 36: 737–42
   PubMedGoogle Scholar
• Fretland D J, Djuric S W, Gaginella T S. Eicosanoids and inflammatory bowel disease: regulation and prospects for therapy. Prostaglandins Leukot Essent Fatty Acids 1990; 41: 215–33
   PubMedGoogle Scholar
• Davies P, Bailey P J, Goldenberg M, Ford-Hutchinson A W. The role of arachidonic acid oxygenation products in pain and inflammation. Annu Rev Immunol 1984; 2: 335–57
   PubMed Web of Science ®Google Scholar
• Parker C W. Lipid mediators produced through the lipoxygenase pathway. Annu Rev Immunol 1987; 5: 65–84
   PubMedGoogle Scholar
• Lewis R A, Austen K F, Soberman R J. Leukotrienes and other products of the 5-lipoxygenase pathway. Biochemistry and relation to pathobiology in human diseases. N Engl J Med 1990; 323: 645–55
   PubMed Web of Science ®Google Scholar
• Stenson W F. Platelet-activating factor and inflammatory bowel disease. Gastroenterology 1988; 95: 1416–9
   PubMedGoogle Scholar
• Hanahan D. Platelet activating factor: a biologically active phosphoglyceride. Annu Rev Biochem 1986; 55: 483–509
   PubMed Web of Science ®Google Scholar
• Sturk A, ten Cate K W, Hosford D, Mencia-Huerta J M, Braquet P. The synthesis, catabolism, and pathophysiological role of platelet-activating factor. Adv Lipid Res 1989; 23: 219–76
   PubMedGoogle Scholar
• Owen D AA. Inflammation—histamine and 5-hydroxytryptamine. Br Med Bull 1987; 43: 256–69
   PubMed Web of Science ®Google Scholar
• Proud D, Kaplan A P. Kinin formation: mechanisms and role in inflammatory disorders. Annu Rev Immunol 1988; 6: 49–83
   PubMed Web of Science ®Google Scholar
• Gaginella T S, Kachur J F. Kinins as mediators of intestinal secretion. Am J Physiol 1989; 256: G1–15
   Google Scholar
• Sharma J N, Mohsin S S. The role of chemical mediators in the pathogenesis of inflammation with emphasis on the kinin system. Exp Pathol 1990; 38: 73–96
   PubMedGoogle Scholar
• Joiner K A, Brown E J, Frank M M. Complement and bacteria: chemistry and biology in host defense. Annu Rev Immunol 1984; 2: 461–91
   PubMed Web of Science ®Google Scholar
• Müller-Eberhard H J. The membrane attack complex of complement. Annu Rev Immunol 1986; 4: 503–28
   Google Scholar
• Jose P J. Complement-derived peptide mediators of inflammation. Br Med Bull 1987; 43: 336–49
   PubMedGoogle Scholar
• Elmgreen J. Complement and function of neutrophils in chronic inflammatory bowel disease. Dan Med Bull 1986; 33: 222–8
   PubMed Web of Science ®Google Scholar
• Ahrenstedt O, Knutson L, Nilsson B, Nilsson-Ekdahl K, Odlind B, Hallgren R. Enhanced local production of complement components in the small intestines of patients with Crohn's disease. N Engl J Med 1990; 332: 1345–9
   Google Scholar
• Halstensen T S, Mollnes T E, Garred P, Fausa O, Brandtzaeg P. Epithelial deposition of immunoglobulin G1 and activated complement (C3b and terminal complement complex) in ulcerative colitis. Gastroenterology 1990; 98: 1264–71
   PubMed Web of Science ®Google Scholar
• Dinarello C A. Interleukin-1. Dig Dis Sci 1988; 33 Suppl: 25S–35S
   Google Scholar
• Fiocchi C. Lymphokines and the intestinal immune response. Role in inflammatory bowel disease. Immunol Invest 1989; 18: 91–102
   PubMed Web of Science ®Google Scholar
• O'Garra A. Interleukins and the immune system 1/2. Lancet 1989; i: 943–7; 1003–5
   Google Scholar
• Arai K I, Lee F, Miyatake S, Arai N, Yokota T. Cytokines: coordinators of immune and inflammatory responses. Annu Rev Biochem 1990; 59: 783–836
   PubMed Web of Science ®Google Scholar
• Warren J S. Interleukins and tumor necrosis factor in inflammation. Crit Rev Clin Lab Sci 1990; 28: 37–59
   PubMed Web of Science ®Google Scholar
• Pober J S, Cotran R S. Cytokines and endothelial cell biology. Physiol Rev 1990; 70: 427–51
   PubMed Web of Science ®Google Scholar
• Rubin L A, Nelson D L. The soluble interleukin-2 receptor: biology, function, and clinical application. Ann Intern Med 1990; 113: 619–27
   PubMed Web of Science ®Google Scholar
• Kühn R, Löhler J, Rennick D, Rakewsky K, Müller W. Interleukin-10-deficient mice develop chronic enterocolitis. Cell 1993; 75: 263–74
   PubMed Web of Science ®Google Scholar
• Nast C C, LeDuc L E. Chemotactic peptides. Mechanisms, functions, and possible role in inflammatory bowel disease. Dig Dis Sci 1988; 33 Suppl: 50S–7S
   Google Scholar
• Shanahan F, Anton P. Neuroendocrine modulation and the immune system. Possible implications for inflammatory bowel disease. Dig Dis Sci 1988; 33 Suppl: 41S–9S
   Google Scholar
• Mayer E M, Raybould H, Koelbel C. Neuropeptides, inflammation, and motility. Dig Dis Sci 1988; 33 Suppl: 71S–7S
   Google Scholar
• Payan D G. Neuropeptides and inflammation. The role of substance P. Annu Rev Med 1989; 40: 341–52
   PubMed Web of Science ®Google Scholar
• Eliakim R, Karmeli F, Ohon E, Rachmilewitz D. Octreotide effectively decreases mucosal damage in experimental colitis. Gut 1993; 34: 264–9
   PubMedGoogle Scholar
• Parks D A. Oxygen radicals: mediators of gastrointestinal pathophysiology. Gut 1989; 30: 293–8
   PubMed Web of Science ®Google Scholar
• Grisham M B, Granger D N. Neutrophil-mediated mucosal injury. Role of reactive oxygen metabolites. Dig Dis Sci 1988; 33 Suppl: 6S–15S
   Google Scholar
• McCord J M. Oxygen-derived free radicals in postischemic tissue injury. N Engl J Med 1985; 312: 159–63
   PubMed Web of Science ®Google Scholar
• Grisham M B. Role of reactive oxygen metabolites in inflammatory bowel disease. Curr Opin Gastroenterol 1993; 9: 971–80
   Web of Science ®Google Scholar